by Alison Bass | Sep 4, 2012 | antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration
In the wake of GlaxoSmithKline’s record-breaking $3 billion settlement with the U.S. Department of Justice, a number of psychiatrists and researchers have redoubled their efforts to get Paxil study 329 retracted. As mentioned here and in other news accounts, the...
by Alison Bass | Aug 7, 2012 | antidepressants, clinical trials, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration
The Chronicle of Higher Education this week ponders why various universities have taken no action against the academic researchers who co-authored the notorious Paxil study that formed the crux of GlaxoSmithKline’s recent $3 billion settlement with the...
by Alison Bass | Jul 3, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing
I was glad to see that the New York Times’ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by the name of Rose...
by Alison Bass | Jun 7, 2012 | biotech industry, clinical trials, conflicts of interest, pharmaceutical industry, Uncategorized
Senator Charles Grassley is upping the ante on the controversy surrounding the Vertex pharmaceutical executives who cashed in on overstated clinical trial data — see my blog from last week. According to The Boston Globe, which broke the Vertex story, Grassley...
by Alison Bass | May 30, 2012 | biotech industry, clinical trials, conflicts of interest, drug marketing, pharmaceutical industry, Uncategorized
Senior executives at Vertex Pharmaceuticals made millions of dollars each by selling company stock in the days after the Cambridge-based pharmaceutical reported promising clinical trial data on an experimental drug for cystic fibrosis. And then weeks after they cashed...
by Alison Bass | May 16, 2012 | clinical trials, conflicts of interest, drug marketing, FDA, medical devices, pharmaceutical industry, public health
Congress is moving quickly to pass a bill that would authorize higher industry fees for the FDA in exchange for speeding up the approval of some drugs and medical devices and eliminating restrictions on financial conflicts of interest among the agency’s advisory...
